Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 24,800 shares of Opko Health stock in a transaction that occurred on Monday, October 10th. The stock was purchased at an average cost of $9.82 per share, for a total transaction of $243,536.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $30,137,098.82. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, October 6th, Phillip Md Et Al Frost bought 4,200 shares of Opko Health stock. The shares were bought at an average cost of $10.53 per share, for a total transaction of $44,226.00.
  • On Tuesday, October 4th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were bought at an average cost of $10.57 per share, for a total transaction of $38,052.00.
  • On Friday, September 30th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.54 per share, for a total transaction of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were bought at an average cost of $10.67 per share, for a total transaction of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were bought at an average cost of $11.01 per share, for a total transaction of $59,454.00.
  • On Tuesday, September 27th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $11.16 per share, for a total transaction of $20,088.00.
  • On Monday, September 26th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $11.04 per share, for a total transaction of $19,872.00.
  • On Friday, September 23rd, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.95 per share, for a total transaction of $19,710.00.
  • On Thursday, September 22nd, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.63 per share, for a total transaction of $19,134.00.
  • On Wednesday, September 21st, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average cost of $10.46 per share, for a total transaction of $18,828.00.

Shares of Opko Health Inc. (NYSE:OPK) opened at 9.66 on Wednesday. The firm has a market capitalization of $5.32 billion and a P/E ratio of 40.42. Opko Health Inc. has a 1-year low of $7.12 and a 1-year high of $11.85. The stock’s 50 day moving average is $10.06 and its 200 day moving average is $10.09.

Opko Health (NYSE:OPK) last released its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The company earned $357.10 million during the quarter, compared to analysts’ expectations of $324.11 million. Opko Health’s revenue was up 742.2% on a year-over-year basis. During the same period last year, the firm posted ($0.09) earnings per share. Equities analysts predict that Opko Health Inc. will post ($0.05) earnings per share for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

A number of equities analysts have recently issued reports on the stock. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Oppenheimer Holdings Inc. reiterated an “outperform” rating on shares of Opko Health in a research note on Saturday, June 25th. Standpoint Research increased their price objective on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, June 21st. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, Deutsche Bank AG dropped their price objective on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research note on Thursday, June 16th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Opko Health has a consensus rating of “Buy” and an average target price of $13.20.

Large investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new stake in Opko Health during the second quarter worth about $100,000. Financial Architects Inc increased its stake in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock worth $102,000 after buying an additional 1,940 shares during the period. First Citizens Bank & Trust Co. bought a new stake in Opko Health during the second quarter worth about $103,000. Williams Jones & Associates LLC increased its stake in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock worth $106,000 after buying an additional 8,800 shares during the period. Finally, Nuveen Fund Advisors LLC bought a new stake in Opko Health during the second quarter worth about $131,000.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.